白蛋白结合型紫杉醇联合铂类药物对比吉西他滨联合铂类药物一线治疗中晚期肺鳞癌的临床疗效观察#br# #br#

目的观察白蛋白结合型紫杉醇联合铂类化疗药物对比吉西他滨联合铂类化疗药物一线治疗中晚期肺鳞癌患者的安全性和有效性。方法选择2016年6月至2021年3月徐州医科大学附属医院收治的68例存在手术禁忌证的中晚期肺鳞癌患者作为研究对象，根据化疗方案不同，分为白蛋白结合型紫杉醇联合铂类组（NAB P组）和吉西他滨联合铂类组（GEM组），分析两组患者的临床疗效及不良反应。结果NAB P组的客观缓解率为3056%，GEM组的客观缓解率为2813%，两组比较差异无统计学意义（P＞005）；NAB P组的疾病控制率为8611%，GEM组的疾病控制率为6563%，两组比较差异有统计学意义（P＜005）；不良反应方面， NAB P组的周围神经毒性、脱发、黏膜炎发生率高于GEM组（P＜005）；GEM组血小板降低的发生率高于NAB P组（P＜005）；NAB P组的无进展生存时间较GEM组长（P＜005），但1年生存率两组差异无统计学意义（P＞005）。结论白蛋白结合型紫杉醇联合铂类药物一线治疗中晚期肺鳞癌比吉西他滨联合铂类药物在疗效上更有优势，且NAB P组的不良反应轻，值得临床进一步推广。

Clinical observation of nab-paclitaxel plus platinum versus gemcitabine plus platinum as first-line treatment in patients with advanced lung squamous cell carcinoma

ObjectiveTo compare the clinical efficacy and adverse reactions of nab paclitaxel plus platinum versus gemcitabine plus platinum in the first line treatment of advanced lung squamous cell carcinoma. MethodsSixty eight patients with advanced lung squamous cell carcinoma who had surgical contraindications treated in the Affiliated Hospital of Xuzhou Medical University from June 2016 to March 2021 were selected and treated with nab paclitaxel plus platinum (NAB P group) and gemcitabine plus platinum (GEM group) as the first line treatment respectively. The clinical efficacy and adverse reactions of the two groups were compared. ResultsThere was no significant difference on objective remission rate between NAB P group (3056%) and GEM group (2813%). The disease control rate of NAB P group was significantly higher than that of GEM group (8611% vs 6563%, P<005). The incidences of peripheral neurotoxicity, alopecia and mucositis in NAB P group were higher than those in GEM group (P<005). The incidence of thrombocytopenia in GEM group was higher than that in NAB P group (P<005). The progression free survival time in NAB P group was longer than that in GEM group (P<005). However, there was no significant difference on one year survival rate between the two groups (P>005). ConclusionsNab paclitaxel combined with platinum in the first line treatment of advanced lung squamous cell carcinoma is more effective than gemcitabine combined with platinum with fewer adverse reactions, which is worthy of further clinical promotion.